Insiders Trading INCY, LOPE, STMP, HMA

By Jonathan Moreland, founder of Insider Insights and author of Profit From Legal Insider Trading.

NEW YORK ( TheStreet) -- Which insiders are selling and buying chunks of stocks?

Below are lists of the top 10 open-market insider purchases and sales filed at the Securities and Exchange Commission Friday, January 20, 2012 as ranked by dollar value. Company executives and directors are in the best position to assess the attractiveness of their firms' shares, and here is how many of them are voting their wallets! Please note, however, that these are factual lists, not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction.

Incyte (INCY) Brooke Paul A DIR 50,000 $884,750
Cracker Barrel (CBRL) Biglari Sardar BO 4,100 $215,570
Moduslink Global Solutions (MLNK) Handy & Harman BO 31,806 $176,620
Health Management (HMA) Gillespie Kerrin E VP,OO
FO
25,000 $152,497
GP Strategies (GPX) Sagard Capital Partners BO 11,572 $151,617
Alexza Pharmaceuticals (ALXA) Occitan Capital Management BO 179,041 $145,768
Ventas (VTR) Gilchrist Richard I DIR 2,500 $138,573
Christopher & Banks (CBK) Waller Joel N PR 25,000 $50,250
Command Security (MOC) Smith David E BO 18,000 $28,951
Unilife (UNIS) Shortall Alan CEO,DIR 4,750 $17,900
Source: www.InsiderInsights.com
Mastercard (MA) Mastercard Foundation BO 21,090 $7,381,509
Synnex (SNX) Miau Matthew DIR 203,800 $7,274,020
Grand Canyon Education (LOPE) Richardson Brent D CB,DIR 250,000 $4,137,500
Grand Canyon Education (LOPE) Richardson Christopher C GC,DIR 250,000 $4,137,500
Stamps.Com (STMP) Miller Lloyd I III DIR 166,945 $5,052,407
Chicago Bridge & Iron (CBI) Petterson Lasse COO 41,400 $1,738,800
Jabil Circuit (JBL) Paver Robert L SEC,GC 62,773 $1,453,691
LPL Investment Holdings (LPLA) Putnam James S DIR 40,000 $1,360,184
Synchronoss Technologies (SNCR) Waldis Stephen G CEO,CB
DIR
40,000 $1,236,800
Jabil Circuit (JBL) Morean William D DIR 40,400 $896,858
Source: www.InsiderInsights.com

Key to Titles: A=Assistant, AI=Affiliated Investor, AO=Accounting Officer, BD=Business Development, BO=Beneficial Owner, CAO=Chief Accounting Officer, CB=Chairman, CCO=Chief Compliance Officer, CEO=Chief Executive Officer, CFO=Chief Financial Officer, CIO=Chief Information Officer, CO=Compliance Officer, COO=Chief Operating Officer, CT=Controller, CTO=Chief Technology Officer, DIR=Director, EVP=Executive Vice President, F=Founder, FO=Financial Officer, GC=General Counsel, HR=Human Resources, IO=Information Officer, IR=Investor Relations, LO=Legal Officer, MD=Managing Director, O=Officer, OO=Operating Officer, PR=President, PT=Partner, REL=Relative of an insider, SEC=Secretary, SH=Shareholder, SO=Sales Officer, TO=Technology Officer, TR=Treasurer, TT=Trustee, VCB=Vice Chairman, VP=Vice President, X=Ex Officer or other title displayed.
Jonathan Moreland is the founder of InsiderInsights.com, which produces a weekly newsletter and offers professional screening and alerting tools to analyze a proprietary, real-time insider data feed. He is also the principal of Insider Asset Management, a registered investment advisor in New York. Mr. Moreland has been analyzing insider data professionally for two decades and has been a contributor to TheStreet.com since 2001. A fundamental analyst with an MBA in finance, Mr. Moreland long ago identified insider data as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis and stock recommendations stemming from it. He is also author of Profit From Legal Insider Trading.

Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. While he cannot provide investment advice or recommendations, Moreland appreciates your feedback; click here to send him an email.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)